Dr. Greg Marchand has served as Principal Investigator on eight industry-sponsored FDA clinical trials in women’s health. Each is listed below with its ClinicalTrials.gov registry identifier, sponsor and phase, so that the protocol and results can be verified independently rather than taken on trust.
Trial work is conducted at the Marchand Institute’s Mesa, Arizona site. It is kept structurally separate from Dr. Marchand’s evidence-synthesis program: no sponsor of a trial funds, reviews or influences any systematic review or meta-analysis he publishes.
Trials With Dr. Marchand as Principal Investigator
| Trial | Phase | Sponsor | Registry ID | Site years |
|---|---|---|---|---|
| SPIRIT 1 — Relugolix with and without low-dose estradiol and norethindrone acetate for endometriosis-associated pain | Phase 3 | Myovant Sciences | NCT03204318 | 2018–2020 |
| RAQUEL — Quinagolide vaginal rings administered sequentially over eight menstrual cycles for moderate-to-severe endometriosis-related pain | Phase 2 | Ferring Pharmaceuticals | NCT03692403 | 2019–2022 |
| EVOGUARD — EVO100 for prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women with risk factors | Phase 3 | Evofem | NCT04553068 | 2020–2022 |
| Okamoto 510(k) — Randomized, double-blind, cross-over investigational device trial of a lubricated polyurethane device in human reproduction and sexual health | 510(k) device study | Okamoto | Investigational device study; not registered on ClinicalTrials.gov | 2021–2023 |
| SERENE — Safety and contraceptive efficacy of relugolix combination therapy in women with uterine fibroids or endometriosis at risk for pregnancy | Phase 3 | Sumitomo Pharma Switzerland | NCT04756037 | 2022–2024 |
| MOXIE (MVT-601A-006) — Bone mineral density with long-term use of relugolix combination tablet in premenopausal women with heavy menstrual bleeding from fibroids or endometriosis-associated pain | Phase 3B | Sumitomo Pharma Switzerland | NCT05862272 | 2023–2025 |
| Estetrol for female sexual arousal disorder — Proof-of-concept study of estetrol in postmenopausal subjects with FSAD | Phase 2 | Estetra | NCT06308614 | 2024–present |
| SUNFLOWER — Resolution of nonatypical endometrial hyperplasia with the 52 mg levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate over six months | Phase 3 | Bayer | NCT06904274 | 2025–present |
Grant Applications Under Review
Dr. Marchand is an NIH Early Stage Investigator, eligible through March 2031. Two federal applications are currently submitted and under review:
- NIH R21 (PA-25-304) — Development and Feasibility Testing of a Non-Morcellating Minimally Invasive Surgical Tissue Removal System. Exploratory/Developmental Research Project Grant. Submitted May 2026; proposed project period 2026–2028. Not yet funded.
- NIH R01 (PA-25-301) — A Non-Inferiority Comparative Effectiveness Study of Ultra-Minimally Invasive versus Conventional Gynecologic Surgery for Endometriosis. NICHD Research Project Grant. Submitted June 2026; proposed project period 2026–2031. Under review, not yet funded.
How Trial Work Relates to Dr. Marchand’s Independence
Dr. Marchand’s role in the studies above is as a clinical trial site principal investigator: his site enrolls and follows participants under a sponsor’s protocol. Site participation is compensated at fair market value for the clinical work performed, as it is at every trial site.
This is separate from, and does not fund, his research program. Dr. Marchand holds no consulting agreements, advisory fees, speaking fees, equity or royalties from any pharmaceutical or medical device company, and no sponsor has any role in selecting, conducting, interpreting or reporting his systematic reviews and meta-analyses. He openly declares no conflicts of interest. Read the full independence and funding statement.
For Sponsors and Investigators
Dr. Marchand considers new site participation in gynecologic surgery, endometriosis, fibroid, contraception and general women’s health trials. Inquiries from sponsors, CROs and academic coordinating centers can be directed to maria@marchandobgyn.com or through his collaboration page.
For Patients
This page is provided for transparency and does not constitute an offer to enroll. Trial availability changes, and eligibility is determined by each protocol. If you are interested in whether a study is currently enrolling, please call (480) 999-0905 and speak with his clinical team, or search ClinicalTrials.gov directly. Nothing on this page is medical advice.